請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70146
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳基旺 | zh_TW |
dc.contributor.advisor | Ji-Wang Chern | en |
dc.contributor.author | 張峻瑋 | zh_TW |
dc.contributor.author | Chun-Wei Chang | en |
dc.date.accessioned | 2021-06-17T03:46:03Z | - |
dc.date.available | 2023-11-30 | - |
dc.date.copyright | 2018-03-29 | - |
dc.date.issued | 2017 | - |
dc.date.submitted | 2002-01-01 | - |
dc.identifier.citation | 第六章、參考文獻
1. 衛生福利部網站 http://www.mohw.gov.tw/CHT/Ministry/Index.aspx 2. 101年12月高醫醫訊月刊第三十二卷第七期 談乳癌標靶治療 乳房腫瘤外科陳芳銘主治醫師 http://www.kmuh.org.tw/www/kmcj/data/10112/14.htm 3. Siegel R. L.; Miller K.D.; Jemal A. Cancer Statistics, 2017.CA Cancer J Clin, 2017, 1, 7–30. 4. Marcucci F.; Stassi G.; De Maria R. Epithelial–mesenchymal transition: a new target in anticancer drug discovery. Nat. Rev. Drug Discov. 2016, 5, 311–325. 5. Hennessy B. T.; Smith D. L.; Ram P. T.; Lu Y.; Mills G. B.; Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 12, 988–1004. 6. Woo S.U.; Sangai T.; Akcakanat A.; Chen H.; Wei C.; Meric-Bernstam F. Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. Oncogenesis, 2017, 6, e385. 7. Millis S. Z.; Ikeda S.; Reddy S.; Gatalica Z.; Kurzrock R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19784 diverse solid tumors. JAMA Oncol., 2016, 2, 1565–1573. 8. Liu P.; Cheng H.; Roberts T. M.; Zhao J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8, 627–644. 9. Holmes D. PI3K pathway inhibitors approach junction. Nat. Rev. Drug Discov. 2011, 10, 563–564. 10. Benjamin D.; Colombi M.; Moroni C.; Hall M. N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011, 10, 868–880. 11. Jerusalem G.; Rorive A.; Collignon J. Breast Cancer: Targets and Therapy. 2014, 6, 43–657. 12. Faivre S.; Kroemer G.; Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5, 671–688. 13. Rodrik-Outmezguine V. S; Okaniwa M.; Yao Z.; Novotny C.J.; McWhirter C.; Banaji A.; Won H.; Wong W.; Berger M.; de Stanchina E.; Barratt D. G.; Cosulich S.; Klinowska T.; Rosen N.; Shokat K. M. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 2016, 534, 272–276. 14. Liu Q.; Chang J. W.; Wang J.; Kang S. A.; Thoreen C. C.; Markhard A.; Hur W.; Zhang J.; Sim T.; Sabatini D. M.; Gray N. S. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h ][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53, 7146–7155. 15. Liu Q.; Wang J.; Kang S.A.; Thoreen C. C.; Hur W.; Ahmed T.; Sabatini D. M.; Gray N. S.; Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J. Med. Chem. 2011, 54, 1473-1480. 16. Yang H.; Rudge D. G.; Koos J. D.; Vaidialingam B.; Yang H. J.; Pavletich N. P. mTOR kinase structure, mechanism and regulation. Nature 2013, 497, 217–223. 17. Zhang Y.; Zhang K.; Zhao M.; Zhang L.; Qin M.; Guo S.; Zhao Y.; Gong P. Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations. Bioorg. Med. Chem. 2015, 23, 4591–4607. 18. Blakemore J. D.; Chalkley M. J.; Farnaby J. H.; Guard L. M.; Hazari N.; Incarvito C. D.; Luzik Jr. E. D.; Suh H. W. New Bidentate Trans-Chelating N-Heterocyclic Carbene Ligands for Palladium. Organometallics. 2011, 30, 1818–1829. 19. Zahouily M.; Bahlaouan B.; Rayadh A.; Sebti S. Natural Phosphates and Potassium Fluoride Doped Natural Phosphate: Efficient Catalyst for the Construction of a Carbon-Nitrogen Bond. Tetrahedron Letters 2004, 45, 4135–4138. 20. Shaikh N. S.; Deshpande V. H.; Bedekar A. V. Clay catalyzed chemoselective Michael type addition of aliphatic amines to α,β-ethylenic compounds. Tetrahedron 2001, 57, 9045-9048. 21. Deshmukh M. N.; Sampath Kumar U.; Rama Rao A. V. Titanium Mediated Cyclization of N-Substituted Di(β-Carbethoxyethyl)amines: Preparation of 1-Substituted-3-carbethoxy-4-piperidones, Synthetic Communications 1995, 25, 177–182. 22. Jung M. H.; Hong J. H.; Cho J. H.; Oh C. H. Synthesis and In-Vitro Activity of New 1b-Methylcarbapenem Derivatives as Antibacterial Agents. Arch. Pharm. Chem. Life Sci. 2008, 341, 780–786. 23. Desmarets C.; Champagne B.; Walcarius A.; Bellouard C.; Omar-Amrani R.; Ahajji A.; Fort Y.; Schneider R. Facile synthesis and characterization of naphthidines as a new class of highly nonplanar electron donors giving robust radical cations. J. Org. Chem. 2006, 71, 1351–1361. 24. Gozalbes R.; Simon L.; Froloff N.; Sartori E.; Monteils C.; Baudelle R. Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries. J. Med. Chem. 2008, 51, 3124–3132. 25. Scope and limitations of Pd2(dba)3/P(i-BuNCH2CH2)3N-catalyzed Buchwald-Hartwig amination reactions of aryl chlorides. J. Org. Chem. 2004, 69, 9135–9142. 26. Wolfe J. P.; Buchwald S. L. Room Temperature Catalytic Amination of Aryl Iodides. J. Org. Chem. 1997, 62, 6066–6068. 27. Wolfe J. P.; Buchwald S. L. Buchwald. Scope and Limitations of the Pd/BINAP-Catalyzed Amination of Aryl Bromides. J. Org. Chem. 2000, 65, 1144–1157. 28. Buckley B. R.; Christie S. D. R.; Elsegooda M. R. J.; Gillingsa C. M.; Gillingsa, Page P. C. B.; Pardoe W. J. M. An Aromatic Amination Approach towards Ancistrocladinium A/B. Synlett. 2010, 6, 939–943. 29. Beletskaya I. P.; Cheprakov A. V. Copper in cross-coupling reactions The post-Ullmann chemistry Coordination Chemistry Reviews. 2004, 248, 2337–2364. 30. Rao H.; Fu H.; Jiang Y.; Zhao Y. Copper-catalyzed arylation of amines using diphenyl pyrrolidine-2-phosphonate as the new ligand. J. Org. Chem. 2005, 70, 8107–8109. 31. Zhang H.; Cai Q.; Ma D. Amino Acid Promoted CuI-Catalyzed C-N Bond Formation between Aryl Halides and Amines or N-Containing Heterocycles. J. Org. Chem. 2005, 70, 5164–5173. 32. Quach T. D.; Batey R. A. Ligand- and base-free copper(II)-catalyzed C-N bond formation: cross-coupling reactions of organoboron compounds with aliphatic amines and anilines. Org. Lett. 2003, 5, 4397–4400. 33. Kwong F. Y.; Klapars A.; Buchwald S. L. Copper-catalyzed coupling of alkylamines and aryl iodides: an efficient system even in an air atmosphere. Org. Lett. 2002, 4, 581–584. 34. Ma D.; Cai Q.; Zhang H. Mild method for Ullmann coupling reaction of amines and aryl halides. Org. Lett. 2003, 5, 2453–2455. 35. Kelly, M. G.; Kincaid, J.; Kaub, C. J. Fused heterocyclic compounds, and compositions and uses thereof. US 20060258689 A1. 36. Ma X.; Lv X.; Qiu N.; Yang B.; He Q.; Hu Y. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation. Bioorg. Med. Chem. 2015, 23, 7585–7596. 37. Yunxin Y. B.; Shon B.; Marian B.; Holly L. D.; Longbin L.; Kristin A.; Nobuko N.; Mark H. N.; Kathleen P.; Laurie S.; Aaron C. S.; Nuria A. T.; Kevin Y.; Inhibitors of pi3 kinase. WO2009155121 A2. 38. Mitchinson A.; Atack J. R.; Blurton P.; Carling R. W.; Castro J. L.; Curley K. S.; Russell M. G.; Marshall G.; McKernan R. M.; Moore K. W.; Narquizian R.; Smith A.; Street L. J.; Thompson S. A.; Wafford K. 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg. Med. Chem. Lett. 2004, 14, 3441–3444. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70146 | - |
dc.description.abstract | 中文摘要
本論文主旨為設計與合成Torin2 (12) 的類似物及四氫吡啶[4,3-d]嘧啶的衍生物作為具有潛能的mTOR蛋白質激酶抑制劑。第一部分以四氫吡啶[4,3-d]嘧啶作為核心結構。將該主結構依序透過氯化、親核性取代反應合成化合物26a-b, 46, 52,去芐基反應後與飽和及不飽和側鏈進行偶合得到化合物29a-b, 29f-h, 30a-e, 48和 54。根據酵素抑制實驗結果顯示,四氫吡啶[4,3-d]嘧啶衍生化合物26a-b, 29a, 29f-h, 30a-e和54對mTOR蛋白質激酶皆失去抑制活性,透過細胞毒性的測試發現,對於不同的癌症細胞株(A549、MCF7、K562),化合物 29f, 29h及 54對於乳癌細胞可以達到µM的毒殺效果。第二部分選用5,6,7,8-四氫-1,6-萘啶結構作為主架構。將該主結構依序透過氯化、親核性取代反應合成化合物61,去乙醯基反應後與不飽和側鏈進行偶合得到化合物63a-b。根據酵素抑制實驗結果顯示,四氫-1,6-萘啶衍生化合物63a-b對mTOR蛋白質皆失去抑制活性。接著透過細胞毒性的測試發現,化合物63b失去對於癌細胞的毒殺效果。推測此兩系列化合物皆失去對於mTOR蛋白之抑制活性的原因為結構四號位置在空間中會有自由旋轉的可能,使得該官能基無法貼近mTOR蛋白的疏水性口袋,無法發揮作用力。 | zh_TW |
dc.description.abstract | Abstract
The aim of this thesis is to design and synthesize tetrahydropyrido[4,3-d]pyrimidine derivatives as potential mTOR kinase inhibitors by replacing the skeleton of pyrido[4,3-d]pyrimidine of Torin2 (12) with new the designated scaffold. In the first target compound, tetrahydropyrido[4,3-d]pyrimidine core structure with different substitutions were connected with saturated or unsaturated side chains after debenzylation, finally afforded the target compounds 29a-b, 29f-h, 30a-e, 48 and 54. Compounds 26a-b, 29a, 29f-h, 30a-e and 54 were then subjected to enzymatic assay and did not show any significant inhibitory activity against mTOR kinase at 10 M concentration. In addition, compounds 29f, 29h, 30c, 48 and 54 were also conducted antiproliferative assay against a variety of cancer cell lines. However, compounds 29f, 29h and 54 showed weak activity against breast cancer cell lines at µM range. In the second target compound, we changed the skeleton with tetrahydro-1,6-naphthyridine core structure which were then connected with unsaturated side chains after deacetylation, finally afforded the target compounds 63a-b. Compounds 63a-b did not show any activity against mTOR kinase. We conclude that the synthesized compounds lost activity against mTOR probably due to the core structures of two types of compounds too flexible. We further propose that the more rigid and plain skeleton of compounds will be better fitting into the active site of mTOR instead of the flexible one. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:46:03Z (GMT). No. of bitstreams: 1 ntu-106-R04423015-1.pdf: 6030166 bytes, checksum: 7ac965468a2e2a8064ccc4557c9aca97 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 目錄
口試委員會審定書.........................................i 致謝...................................................ii 目錄..................................................iii 圖表目錄................................................v 表目錄.................................................vi 反應圖示目錄...........................................vii Abstract.............................................viii 中文摘要................................................ix 縮寫對照表...............................................x 第一章、緒論.............................................1 第一節、前言...........................................1 第二節、乳癌...........................................2 第三節、PI3K/AKT/mTOR訊息傳遞路徑.......................4 第四節、mTOR (Mammalian target of rapamycin)...........6 第五節、mTOR蛋白質激酶抑制劑之發展.......................7 第二章、實驗動機與合成 ..................................11 第一節、結構設計構....................................11 第二節、Tetrahydropyrido[4,3-d]pyrimidine (THPP) 結構的 衍生物之設計構想及合成想法......................12 第三節、5,6,7,8-Tetrahydro-1,6-naphthyridine環的衍生物之 設計構想及合成方法.............................24 第三章、結果與討論......................................28 第四章、結論............................................35 第五章、實驗部份........................................37 第一節、重要儀器與材料.................................37 第二節、合成方法......................................38 第三節、In vitro mTOR Kinase Activity Assay...........67 第四節、Cell Culture and Anti-proliferation Assay.....68 第六章、參考文獻........................................69 Appendix for Spectrum of 1H NMR and 13C NMR............75 第七章、Spectrum of 1H NMR and 13C NMR...............- 1 - | - |
dc.language.iso | zh_TW | - |
dc.title | 設計與合成四氫吡啶[4,3-d]嘧啶衍生物作為mTOR抑制劑 | zh_TW |
dc.title | Design and Synthesis of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine Derivatives as Mammalian Target of Rapamycin (mTOR) Inhibitors | en |
dc.type | Thesis | - |
dc.date.schoolyear | 106-1 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 顧記華;忻凌偉;梁碧惠 | zh_TW |
dc.contributor.oralexamcommittee | Jih-Hwa Guh;Ling-Wei Hsin;Pi-Hui Liang | en |
dc.subject.keyword | 哺乳動物雷帕黴素靶蛋白質激?,哺乳動物雷帕黴素靶蛋白質激?抑制劑,PI3K/AKT/mTOR 訊息傳遞路徑,乳癌,四氫?啶[4,3-d]嘧啶結構衍生物,四氫-1,6-?啶結構衍生物, | zh_TW |
dc.subject.keyword | mTOR,mammalian target of rapamycin,mTOR inhibitors,PI3K/AKT/mTOR signaling pathway,breast cancer,5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine derivatives,5,6,7,8-tetrahydro-1,6-naphthyridine derivatives, | en |
dc.relation.page | 124 | - |
dc.identifier.doi | 10.6342/NTU201800193 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2018-01-30 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 藥學研究所 | - |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 5.89 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。